Details of the Drug

General Information of Drug (ID: DMEMV9D)

Drug Name

Trimeprazine

Synonyms

Alimemazina; Alimemazine; Alimemazinum; Alimezine; Isobutrazine; Methylpromazine; Oxomemazin; Repetin; Teralen; Trimeperazine; Trimeprazine Tartrat; Bayer 1219; Alimemazina [INN-Spanish]; Alimemazine (INN); Alimemazine [INN:BAN]; Alimemazinum [INN-Latin]; Dl-Trimeprazine; Nedeltran (TN); Oxomemazine [DCF:INN]; Panectyl (TN); Repeltin (TN); Temaril (TN); Therafene (TN); Theralen (TN); Theralene (TN); Trimeprazine (BAN); Vallergan (TN); Vanectyl (TN); Trimeprazine 5,5-dioxide; Trimeprazine hemi-(+)-tartrate; N,N,beta-Trimethyl-10H-phenothiazine-10-propanamine; N,N,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine; N,N,2-trimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine; (+-)-Alimemazine; (+-)-Trimeprazine; 10-(2-Methyl-3-dimethylaminopropyl)-phenothiazine; 10-(3-(Dimethylamino)-2-methylpropyl)phenothiazine; 10-(3-Dimethylamino-2-methylpropyl)phenothiazine

Indication

Disease Entry	ICD 11	Status	REF
Allergic rhinitis	CA08.0	Approved	[1], [2]

Therapeutic Class

Antihistamines

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

298.4

Topological Polar Surface Area (xlogp)

4.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The drug is well absorbed in the digestive tract [3]
Metabolism: The drug is metabolized via the hepatic [3]

Chemical Identifiers

Formula: C18H22N2S
IUPAC Name: N,N,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine
Canonical SMILES: CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)CN(C)C
InChI: InChI=1S/C18H22N2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)21-18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3
InChIKey: ZZHLYYDVIOPZBE-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5574
ChEBI ID: CHEBI:9725
CAS Number: 84-96-8
DrugBank ID: DB01246
TTD ID: D08HZL

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Antagonist	[4]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Allergic rhinitis

ICD Disease Classification

CA08.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Histamine H1 receptor (H1R)	DTT	HRH1	6.74E-01	0.13	0.43

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Trimeprazine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Trimeprazine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[13]
-----------

Coadministration of a Drug Treating the Disease Different from Trimeprazine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Arn-509.	Acute myeloid leukaemia [2A60]	[14]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Oliceridine.	Acute pain [MG31]	[15]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Trimeprazine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[13]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Trimeprazine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[13]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Trimeprazine and Ivabradine.	Angina pectoris [BA40]	[14]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Trimeprazine and Dronedarone.	Angina pectoris [BA40]	[16]
Amyl nitrite	DMJKO05	Moderate	Additive hypotensive effects by the combination of Trimeprazine and Amyl nitrite.	Angina pectoris [BA40]	[17]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Trimeprazine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[18]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Posaconazole.	Aspergillosis [1F20]	[15]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Levalbuterol.	Asthma [CA23]	[19]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Pirbuterol.	Asthma [CA23]	[19]
Ephedrine	DMMV0KW	Moderate	Antagonize the effect of Trimeprazine when combined with Ephedrine.	Asthma [CA23]	[20]
Lisdexamfetamine	DM6W8V5	Moderate	Antagonize the effect of Trimeprazine when combined with Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[20]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Retigabine.	Behcet disease [4A62]	[15]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Trimeprazine and Cariprazine.	Bipolar disorder [6A60]	[13]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Eribulin.	Breast cancer [2C60-2C6Y]	[16]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Lapatinib.	Breast cancer [2C60-2C6Y]	[15]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Bosutinib.	Breast cancer [2C60-2C6Y]	[14]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Trimeprazine when combined with Acetylcholine.	Cataract [9B10]	[21]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[22]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Trimeprazine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[23]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Trimeprazine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[19]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Trimeprazine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[19]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Trimeprazine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[23]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Trimeprazine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[23]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Trimeprazine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[19]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Trimeprazine and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[19]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Trimeprazine and Pasireotide.	Cushing syndrome [5A70]	[24]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Osilodrostat.	Cushing syndrome [5A70]	[25]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Trimeprazine and Isocarboxazid.	Depression [6A70-6A7Z]	[26]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Trimeprazine and Esketamine.	Depression [6A70-6A7Z]	[27]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Trimeprazine and Mepenzolate.	Digestive system disease [DE2Z]	[13]
Tetrabenazine	DMYWQ0O	Major	Additive antidopaminergic effects by the combination of Trimeprazine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[28]
Deutetrabenazine	DMUPFLI	Major	Additive antidopaminergic effects by the combination of Trimeprazine and Deutetrabenazine.	Dystonic disorder [8A02]	[29]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Ingrezza.	Dystonic disorder [8A02]	[30]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Trimeprazine and Solifenacin.	Functional bladder disorder [GC50]	[13]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[16]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[31]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Trimeprazine and Nebivolol.	Hypertension [BA00-BA04]	[17]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Trimeprazine and Levamlodipine.	Hypertension [BA00-BA04]	[17]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Trimeprazine and TAK-491.	Hypertension [BA00-BA04]	[17]
Hydralazine	DMU8JGH	Moderate	Additive hypotensive effects by the combination of Trimeprazine and Hydralazine.	Hypertension [BA00-BA04]	[17]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Trimeprazine and Clevidipine butyrate.	Hypertension [BA00-BA04]	[17]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Trimeprazine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[13]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Trimeprazine and ITI-007.	Insomnia [7A00-7A0Z]	[13]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Trimeprazine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[16]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Trimeprazine and Crizotinib.	Lung cancer [2C25]	[25]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Trimeprazine and Ceritinib.	Lung cancer [2C25]	[24]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Trimeprazine and Osimertinib.	Lung cancer [2C25]	[25]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Trimeprazine and Selpercatinib.	Lung cancer [2C25]	[32]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Trimeprazine and Lumefantrine.	Malaria [1F40-1F45]	[24]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Trimeprazine and Hydroxychloroquine.	Malaria [1F40-1F45]	[33]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[14]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Trimeprazine and Vemurafenib.	Melanoma [2C30]	[16]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and LGX818.	Melanoma [2C30]	[34]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Trimeprazine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[35]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Trimeprazine and Lasmiditan.	Migraine [8A80]	[27]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Trimeprazine and Flibanserin.	Mood disorder [6A60-6E23]	[27]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Trimeprazine and Panobinostat.	Multiple myeloma [2A83]	[36]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Trimeprazine and Fingolimod.	Multiple sclerosis [8A40]	[16]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Trimeprazine and Ozanimod.	Multiple sclerosis [8A40]	[37]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Romidepsin.	Mycosis fungoides [2B01]	[15]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Trimeprazine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[16]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[24]
Dextroamphetamine	DMMIHVP	Moderate	Antagonize the effect of Trimeprazine when combined with Dextroamphetamine.	Narcolepsy [7A20]	[20]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Entrectinib.	Non-small cell lung cancer [2C25]	[14]
Phendimetrazine	DM6TS1N	Moderate	Antagonize the effect of Trimeprazine when combined with Phendimetrazine.	Obesity [5B80-5B81]	[20]
Lorcaserin	DMG6OYJ	Moderate	Decreased metabolism of Trimeprazine caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[35]
Polythiazide	DMCH80F	Moderate	Additive hypotensive effects by the combination of Trimeprazine and Polythiazide.	Oedema [MG29]	[17]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Lofexidine.	Opioid use disorder [6C43]	[24]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Rucaparib.	Ovarian cancer [2C73]	[15]
Methamphetamine	DMPM4SK	Moderate	Antagonize the effect of Trimeprazine when combined with Methamphetamine.	Pain [MG30-MG3Z]	[20]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Triclabendazole.	Parasitic worm infestation [1F90]	[15]
Safinamide	DM0YWJC	Moderate	Additive CNS depression effects by the combination of Trimeprazine and Safinamide.	Parkinsonism [8A00]	[26]
Opicapone	DM1BKA6	Moderate	Antagonize the effect of Trimeprazine when combined with Opicapone.	Parkinsonism [8A00]	[38]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Trimeprazine and Rasagiline.	Parkinsonism [8A00]	[26]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Pimavanserin.	Parkinsonism [8A00]	[25]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Trimeprazine and Methylscopolamine.	Peptic ulcer [DA61]	[13]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Trimeprazine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[25]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Trimeprazine and Lefamulin.	Pneumonia [CA40]	[25]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Degarelix.	Prostate cancer [2C82]	[14]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and ABIRATERONE.	Prostate cancer [2C82]	[14]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Enzalutamide.	Prostate cancer [2C82]	[14]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Trimeprazine and Silodosin.	Prostate hyperplasia [GA90]	[17]
Neupro	DMHEAB1	Moderate	Antagonize the effect of Trimeprazine when combined with Neupro.	Restless legs syndrome [7A80]	[38]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Trimeprazine and Iloperidone.	Schizophrenia [6A20]	[24]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Paliperidone.	Schizophrenia [6A20]	[15]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Trimeprazine and Molindone.	Schizophrenia [6A20]	[13]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Trimeprazine and Thiothixene.	Schizophrenia [6A20]	[13]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Trimeprazine and Amisulpride.	Schizophrenia [6A20]	[39]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Asenapine.	Schizophrenia [6A20]	[16]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Trimeprazine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[16]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Trimeprazine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[24]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[14]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[15]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Trimeprazine and Lenvatinib.	Thyroid cancer [2D10]	[15]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Trimeprazine and Cabozantinib.	Thyroid cancer [2D10]	[14]
-----------


⏷ Show the Full List of 98 DDI Information of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7237).
2	Drug information of Trimeprazine, 2008. eduDrugs.
3	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4	Effectiveness of alimemazine in controlling retching after Nissen fundoplication. J Pediatr Surg. 2005 Nov;40(11):1737-40.
5	Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
6	Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
7	Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
8	Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
9	Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
10	Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
11	Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
12	Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79.
13	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
14	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
15	Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
16	Canadian Pharmacists Association.
17	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
18	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
19	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
20	Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]
21	Multum Information Services, Inc. Expert Review Panel.
22	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
23	Product Information. Anoro Ellipta (umeclidinium-vilanterol). GlaxoSmithKline, Research Triangle Park, NC.
24	Cerner Multum, Inc. "Australian Product Information.".
25	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
26	Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62. [PMID: 14197995]
27	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
28	Login IS, Cronin MJ, MacLeod RM "Neuroleptic malignant syndrome caused by dopamine depleting drugs." Neurology 32 (1982): 1022-5. [PMID: 6119652]
29	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
30	Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
31	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
32	Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
33	Product Information. Hydroxychloroquine Sulfate (hydroxychloroquine). Prasco Laboratories, Cincinnati, OH.
34	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
35	Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
36	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
37	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
38	Product Information. Norprolac (quinagolide). Ferring Inc, North York, IA.
39	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.